SVB Securities analyst Roanna Ruiz reiterated a Hold rating on Atea Pharmaceuticals (AVIR – Research Report) on October 13 and set a price target of $8.00. The company’s shares closed last Friday at $5.25.
Ruiz covers the Healthcare sector, focusing on stocks such as Myovant Sciences, scPharmaceuticals, and Lantheus. According to TipRanks, Ruiz has an average return of -50.9% and a 6.98% success rate on recommended stocks.
Currently, the analyst consensus on Atea Pharmaceuticals is a Moderate Sell with an average price target of $9.00.
See today’s best-performing stocks on TipRanks >>
Based on Atea Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $31.34 million. In comparison, last year the company earned a revenue of $60.39 million and had a net profit of $1.54 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atea Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company’s medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.
Read More on AVIR:
